This is stated on the website of the department.
According to Rospotrebnadzor, this vaccine has successfully passed the phase II-IV open clinical trial among people aged 60 and over.
“As a result of studies that have shown the immunogenicity and high safety of this drug for elderly patients, the EpiVacCorona vaccine was approved for use among people over 60 years old,” the enticement notes.
Earlier, Tatiana Nepomnyashchikh, deputy head of Vector for scientific and methodological work and international cooperation, spoke about the effect of the EpiVacCorona coronavirus vaccine.